References
- Reichert JM. Antibodies to watch in 2014. MAbs 2014; 6:5 - 14; http://dx.doi.org/10.4161/mabs.27333; PMID: 24284914
- Khleif S, Lutzky J, Segal N, Antonia S, Blake-Haskins A, Stewart R, Robbins P, Shalabi A, Ibrahim R, Wolchok J. MEDI4736, an anti-PD-L1 antibody with modified Fc domain: Preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors. European Cancer Congress, September 27-October 1, 2013, Amsterdam, The Netherlands. Abstract #802.
- Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol 2014; 32:40 - 51; http://dx.doi.org/10.1038/nbt.2786; PMID: 24406927